(Q35960898)

11 August 2017

1 reference

title

Treatment of acute and chronic hepatitis C. (English)

1 reference

11 August 2017

1 reference

Davis GL

1

1 reference

11 August 2017

publication date

1 November 1997

1 reference

11 August 2017

published in

Clinics in liver disease

1 reference

11 August 2017

volume

1

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

615-630

1 reference

Epidemiology of Hepatitis C in the West

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Hepatitis C: and miles to go before we sleep.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Interferon in viral hepatitis: role in pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Effect of interferon-alpha 2b on cryoglobulinemia related to hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Side effects of alpha interferon in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Prediction of response to interferon in patients with chronic active hepatitis C, and evidence that this improves hepatic metabolic function

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Interferon-inducible gene expression in chimpanzee liver infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Resolution of acute hepatitis C after therapy with natural beta interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Autoimmune chronic hepatitis exacerbated by alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970325-1

7 January 2021

10.1016/S1089-3261(05)70325-1

Identifiers

DOI

1 reference

11 August 2017

1 reference